KDM1A and acute lymphoblastic leukemia: Taking advantage of such inhibitors, we previously showed that treatment of Zeb2High ETP-ALL cells with the catalytic LSD1i GSK2879552 (hereafter named GSK-LSD1) induces a highly variable pattern of response.